KIR2DL3
KIR2DL3 Molecule Information
Name:Killer cell immunoglobulin-like receptor 2DL3
Target Synonym:NKAT2b;p58 natural killer cell receptor clone CL-6;Killer inhibitory receptor cl 2-3;NKAT2a;MHC class I NK cell receptor;NKAT-2;KIRCL23;Natural killer-associated transcript 2;p58 NK receptor CL-6;KIR2DL3;p58.2 MHC class-I-specific NK receptor;CD158B2 ;KIR
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase ?
KIR2DL3 Molecule Synonym Name
KIR2DL3,CD158B2,KIRCL23,NKAT2,KIR-023GB,NKAT2a,NKAT2b,NKAT-2,CD158 B2,GL183,KIR-023GB,KIR-K7b,KIR-K7c,KIRCL23,NKAT,p58
KIR2DL3 Molecule Background
Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.
KIR2DL3 References
KIR2DL3 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| Lirilumab |
BMS-986015; IPH-21; IPH-2101; IPH-2102; NN-1975 |
Phase Ⅱ |
Novo Nordisk, Bristol-Myers Squibb, Ono Pharmaceutical, Innate |
Myelodysplastic syndrome (MDS), Chronic lymphocytic leukemia (CLL), Head and neck cancer |
Details
|
A-Z